Bei der Logitech G203 unseres Vergleichs von Logitech-Mäusen handelt es sich um Gaming-Maus, die mit einer sehr guten Ergonomie überzeugt. Weiterhin ist uns positiv aufgefallen, dass sie sehr viele ...

Tastaturen sind ausgesprochen vielseitig und stehen für verschiedenste Geräte zur Verfügung. Dazu gehören der PC, Laptop, ...

CSL Limited (ASX:CSL) shares gained 3.5% to around A$123.68 in early trading after the biotechnology group outlined plans for clinical trials to confirm the efficacy and safety of immunoglobulin ...

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals. CSL's investment in advanced manufacturing aligns with its broader push ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated, as plasma sourcing is a key constraint in ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CSL (ASX:CSL) has outlined a restructuring plan that ...

We may receive a commission on purchases made from links. Wireless gaming peripherals are more abundant than ever these days. We're talking everything from mice and keyboards to cable-free headphones ...

After teasing a plasma-based manufacturing expansion in the U.S. late last year, CSL is putting in the work and firming up details behind the $1.5 billion project. Monday, the Australian biopharma ...

Illinois Gov. JB Pritzker on Monday announced a $1.5 billion investment from biotherapeutics company CSL for a new plasma therapy manufacturing plant in Kanakee. CSL will expand its current footprint ...